ARS Pharmaceuticals

ARS Pharmaceuticals

Pharmaceuticals
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

$404.8M

Market Cap • 10/2/2026

2016

(10 years)

Founded

2022

(4 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

32,3

P/S

3,5

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

0,1

EPS

—

Market Cap

Market Cap

404,8M

EV

358,2M

EV/Revenue

3,1

EV/EBITDA

-1,7

EV/EBIT

-1,7

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-0,8%

Total Yield

-0,8%

Payout

0%

Retained Earnings

-417,6M

Profitability

Gross Margin

71,4%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

13%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

—

% PPE

0,8%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

27,3%

CAGR Net Income 5Y

27,3%

CAGR OCF 5Y

34,6%

Leverage

N.D./EBITDA

0,2

Debt/Equity

0%

Current Ratio

3,5

Quick Ratio

3,1

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium